January 30, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Press Release and Management Discussion & Analysis

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the Press Release and Management Discussion & Analysis of the Company for the Third Quarter ended December 31, 2025.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH VINAYAK KUBER
Digitally signed by HARISH VINAYAK KUBER
Date: 2026.01.30 20:09:48 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

Press Release
For Immediate Distribution

glenmark
A new way for a new world

Glenmark Pharmaceuticals Announces Q3 FY26 Results

Highlights for Q3 FY26

- India Formulations revenue up by 22.1% YoY at Rs. 12,986 Mn
- North America revenue grew by 24.2% YoY to Rs. 9,706 Mn (Includes out-licensing income for ISB 2001)
- Europe revenue grew by 9.1% YoY to Rs.7,963 Mn
- Emerging Markets revenue up by 8.4% YoY to Rs. 8,119 Mn
- EBITDA of Rs. 8,697 Mn, 44.9% YoY growth, with an EBITDA margin of 22.3%
- Profit After Tax (PAT) of Rs. 4,032 Mn, 15.9% YoY growth with PAT margin of 10.3%

Mumbai, India, January 30, 2026: Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, today announced its financial results for the third quarter ended December 31, 2025. For the third quarter of FY 2026, Glenmark's consolidated revenue was at Rs. 39,006 Mn as against Rs. 33,876 Mn in the corresponding quarter last year, recording an overall growth of 15.1% YoY.

EBITDA was Rs. 8,697 Mn in the quarter ended December 31, 2025, registering 44.9% YoY growth and an EBITDA margin of 22.3%. Profit After Tax (PAT) for the quarter was Rs. 4,032 Mn, registering 15.9% YoY growth, with a PAT margin of 10.3%.

Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, "We delivered strong double-digit revenue growth in the third quarter, reflecting disciplined execution across markets and keeping us on track to deliver our near-term guidance.

India continued to outperform in our core therapies. In North America, we advanced our portfolio through new launches, pipeline progression, and the positive regulatory outcome at Monroe. Europe and Emerging markets demonstrated improved momentum, supported by our respiratory franchise and expanding global brands.

Our innovative portfolio is shaping up well to become a meaningful growth contributor. RYALTRIS® is scaling across markets, WINLEVI® is gaining traction in the U.K. and has received approval in Europe. Our partnered oncology assets including QiNHAYO™, Trastuzumab Rezetecan and Aumolertinib will strengthen our presence in high-need markets. We are building a more innovation-led Glenmark with a structurally stronger and more sustainable growth trajectory."

About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com

For more information, please contact

Akhila Natarajan | mediarelations@glenmarkpharma.com | +91 98216 89525
Adfactors PR | glenmark@adfactorspr.com | +91 88502 91322

Management Discussion & Analysis
for the Third Quarter of FY 2025-26

Revenue Figures for Glenmark Pharmaceuticals Ltd.

(In Rs. Million)

	Third quarter ended December 31			Nine months ended December 31		
	FY 2025-26	FY 2024-25	Growth (%)	FY 2025-26	FY 2024-25	Growth (%)
India	12,986	10,637	22.1%	27,036	35,415	-23.7%
North America[#]	9,706	7,813	24.2%	62,142	23,026	169.9%
Europe	7,963	7,297	9.1%	22,101	21,128	4.6%
Emerging Markets[##]	8,119	7,491	8.4%	20,426	20,240	0.9%
Total	**38,774**	**33,237**	**16.7%**	**131,704**	**99,809**	**32.0%**
Other Revenue	232	638	-63.6%	416	846	-50.9%
Consolidated Revenue	**39,006**	**33,876**	**15.1%**	**132,119**	**100,655**	**31.3%**

Average conversion rate in 9M FY 2025-26 considered as INR 87.31 / USD 1.00

Average conversion rate in 9M FY 2024-25 considered as INR 83.88 / USD 1.00

USD figures are only indicative

[#] North America revenue for Q3 FY26 and 9M FY26 includes out-licensing income for ISB 2001

[##] Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC)

Review of Operations for the Quarter ended December 31, 2025

For the third quarter of FY26, Glenmark's consolidated revenue from operations was at Rs. 39,006 Mn (USD 435.8 Mn) as against Rs. 33,876 Mn (USD 401.1 Mn) in the corresponding quarter last year, recording overall year-on-year (YoY) growth of 15.1%.

For the nine months of FY26, Glenmark's consolidated revenue was Rs. 132,119 Mn (USD 1,513.2 Mn) as against Rs. 1,00,655 Mn (USD 1,200.0 Mn), recording a YoY growth of 31.3%.

FORMULATION BUSINESS

Glenmark's global formulation business is spread across Branded, Generics, and OTC segments in the therapy areas of Dermatology, Respiratory and Oncology, along with strong regional/country-specific presence in other therapeutic areas like Cardiac, Diabetes and Oral Contraceptives.

INDIA

Sales from the formulation business in India for the third quarter of FY26 was at Rs. 12,986 Mn (USD 147.1 Mn) as against 10,637 Mn (USD 125.8 Mn) in the corresponding quarter last year, recording a growth of 22.1%.

In terms of secondary sales, Glenmark continues to significantly outperform the IPM in terms of YoY growth. As per IQVIA, Glenmark's India formulation business recorded a growth of 15.8% in Q3 FY26 and 13% as per MAT December 2025, compared to the overall market growth of 10.9% in Q3 FY26 and 8.3% in MAT December 2025. Glenmark continued to outperform the overall market in its key therapeutic areas like Dermatology, Respiratory and Cardiac therapeutic areas.

	VALUE GROWTH % (OCT'25 - DEC'25)		VALUE GROWTH % (MAT DEC'25)	
SUPERGROUP	**IPM**	**GLENMARK**	**IPM**	**GLENMARK**
CARDIAC	16.5	20.3	12.6	16.5
DERMATOLOGY	8.8	10.4	5.8	9.6
RESPIRATORY	11.8	13.8	10.0	14.7
DIABETES	14.8	-2.9	9.8	-5.3

Glenmark's India business is ranked 13th with a market share of 2.32% (IQVIA MAT December 2025). The Company has 11 brands in the IPM Top 300 Brands in the country based on IQVIA MAT December 2025. In terms of key therapeutic areas, Glenmark is ranked 2nd in Dermatology, 2nd in Respiratory and 4th in the Cardiac segment as per IQVIA Q3 FY26 data.

	GLENMARK	
SUPERGROUP	MARKET SHARE (%) MAT DEC'24	MARKET SHARE (%) MAT DEC'25
CARDIAC	5.9	6.1
DERMATOLOGY	8.0	8.3
RESPIRATORY	5.7	5.9
DIABETES	1.3	1.1

New Product Launch

In Q3 FY26, Glenmark announced the launch of NEBZMART® GFB Smartules® and Glenmark AIRZ® FB Smartules®, the world's first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Both products combine three proven medicines - Glycopyrronium, Formoterol, and Budesonide - to reduce airway obstruction, inflammation, and improve lung function and symptom control. As a single, easy-to-use nebulized therapy, it minimizes the burden of multiple medications. This marks a breakthrough as a new standard of care for COPD patients, especially those who struggle with using Metered Dose Inhalers (MDI) or Dry Powder Inhalers (DPI). In a clinical study conducted in India, this nebulized triple therapy demonstrated rapid improvement in lung function and better control of breathlessness (dyspnea) among patients. The treatment was well tolerated and demonstrated a good safety profile, offering patients a simpler and more effective way to manage COPD.

TEVIMBRA® (TISLELIZUMAB) & BRUKINSA® (ZANUBRUTINIB) (PARTNERED WITH BEONE)

- Glenmark and BeOne Medicines entered into an agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India in May 2024. Glenmark launched both these products under the respective brand names TEVIMBRA® and BRUKINSA® in Q1 FY26
- In a short period of time, the two brands have seen a very strong uptake in the market as a differentiated treatment option available for patients across multiple solid tumors and hematological malignancies.
- The Company expects these two brands to gain further momentum and meaningfully contribute to the India business growth over the next 2-3 years.

LIRAFIT™

- The Company was the first to launch the biosimilar of Liraglutide under the brand name LIRAFIT in India. LIRAFIT has seen strong traction in the GLP-1 market in India post launch with clear market leadership position.
- The Company also plans to launch other GLP-1 agonists soon.

JABRYUS® (PARTNERED WITH PFIZER)

- In January 2024, Glenmark launched JABRYUS® (Abrocitinib), a first of its kind oral advanced systemic treatment for the treatment of moderate-to-severe atopic dermatitis (AD) in India in partnership with Pfizer.
- JABRYUS® has been well received by dermatologists as a novel treatment for moderate-to-severe AD, with improved efficacy and oral convenience to patients.

INDIA – GLENMARK CONSUMER CARE (GCC)

In Q3 FY26, GCC delivered primary sales growth of 21.5% YoY. The flagship brand CANDID Powder™ delivered revenue growth of 16.7% for Q3 FY26. CANDID Powder has further grown in Q3 FY26 and now holds 56.3% market share as per IQVIA December 2025 dataset. SCALPE™ portfolio delivered strong revenue growth of 51.7% in Q3 FY26. BONTRESS® portfolio delivered revenue growth of 65.5%. Other brands in the portfolio such as ELOVERA® and EPISOFT™ also delivered high double-digit growth during the third quarter.

NORTH AMERICA

The North America business recorded revenues from the sale of finished dosage formulations of Rs. 9,706 Mn (USD 111.2 Mn) for the third quarter of FY26 as against revenue of 7,813 Mn (USD 92.5 Mn) for the third quarter of FY25. Net of the out-licensing income for ISB 2001, the core business YoY growth for the North America region was 4.1% in Q3 FY26.

In the third quarter of FY26, Glenmark launched 4 products: 8.4% Sodium Bicarbonate Injection USP, Ropivacaine Hydrochloride Injection USP, Epinephrine Injection USP – 30 mL Vials, and Leucovorin Calcium for Injection USP, 350 mg. Two ANDAs were filed during the quarter; and Glenmark plans to file three ANDAs in the upcoming quarter.

Glenmark has leveraged its strong development capabilities in the Respiratory area to build a portfolio for the US market. The Company has filed two ANDAs for generic nasal sprays and is awaiting approval for the same. In addition, the Company filed the ANDA for gFlovent® 44mcg pMDI in May 2024 and for gFlovent® 110mcg in December 2025. The Company is working on other respiratory products which are currently in the pipeline and will be filed over the upcoming quarters.

Glenmark's marketing portfolio through December 31, 2025, consists of 214 generic products authorized for distribution in the U.S. market. The Company currently has 53 applications pending in various stages of the approval process with the US FDA, of which 25 are Paragraph IV applications.

In November 2025, Glenmark announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Monroe,

North Carolina (USA) with a Voluntary Action Indicated (VAI) status. With this positive development, the Company will restart commercial manufacturing at the Monroe site.

Note: All brand names and trademarks are the property of their respective owners. IQVIA National Sales Perspectives: Retail and Non-Retail, December 2024

EUROPE

Glenmark Europe operations' revenue for the third quarter of FY26 was at Rs. 7,963 Mn (USD 89.5 Mn) as against Rs. 7,297 Mn (USD 86.4 Mn) recording a growth of 9.1%. There was a strong recovery in the European business during the third quarter due to the onset of the winter season which aided growth of the Respiratory portfolio. As per the latest secondary sales data, Glenmark continued to outperform the covered market in CEE countries such as the Czech, Poland and Slovakia. Five new product launches also aided growth for the region. In the generic markets of Western Europe, Glenmark's performance remained stable with strong achievement in Germany and the Netherlands. The branded Respiratory portfolio in Western European business sustained its growth momentum. The Company continues to focus on sustaining the increasing contribution from the branded markets / portfolio in Europe. Glenmark launched WINLEVI® in the UK market and the brand has seen a strong uptake throughout the year. In October 2025, Glenmark's partner Cosmo received Marketing Authorization (MA) approval for WINLEVI® in the EU. Glenmark is planning to initiate the commercial launch in its licensed EU territories by Q1 FY27.

EMERGING MARKETS (RCIS, LATAM, MEA & APAC)

For the third quarter of FY26, revenue from the EM region was Rs. 8,119 Mn (USD 91.5 Mn) as against Rs. 7,491 Mn (USD 88.8 Mn) for the corresponding quarter last year, recording a growth of 8.4%.

As per IQVIA Q3 FY26 and MAT December 2025 data, Glenmark's Russia business recorded secondary sales growth of 15.1% and 15% in value, respectively. In its core therapeutic area of Dermatology, Glenmark recorded faster secondary sales growth than the overall market. Amongst the Dermatology companies in Russia, Glenmark ranks 9th as per MAT December 2025. Amongst the companies present in the Expectorants market in Russia, Glenmark continues to maintain a strong 2nd rank as per MAT December 2025.

The LATAM region delivered high double-digit growth in the third quarter. Key markets such as Brazil and Mexico witnessed strong recovery on the back of multiple differentiated products launches in the Respiratory segment. Key brands such as RYALTRIS® are expected to sustain high growth and aid the regional business performance in the forthcoming quarters.

In the MEA region, secondary sales growth remained subdued in key markets, mainly on account of some delays in new product launches. RYALTRIS® continues to see strong pick-up post its launch in key markets

in the region. The region is expected to show gradual recovery towards growth starting in the fourth quarter.

Key markets in the APAC region, such as Malaysia and Australia recorded double-digit secondary sales growth during the third quarter. While the Philippines and Sri Lanka markets had a subdued quarter, the overall region is expected to maintain a strong performance in the forthcoming quarters. Glenmark remains the leading Dermatology and Respiratory company in the APAC region. RYALTRIS® continues to do well across the Asia region particularly in key markets.

GLOBAL INNOVATIVE PORTFOLIO UPDATE

RYALTRIS®

- As of December 2025, marketing applications for RYALTRIS® have been submitted to more than 90 countries across the world and the product has been commercialized in 52 markets. Further, it is expected to be launched in additional 10-12 markets over the next few quarters.
- In Q3 FY26, RYALTRIS® commercial launch occurred in Colombia, Nicaragua and El Salvador.
- As per IQVIA September 2025 data across markets, RYALTRIS® has seen robust performance in terms of both value and unit market shares*. RYALTRIS® continues to witness a strong uptake in markets where the product was recently launched across the Europe and EM regions respectively and recorded global secondary sales growth close to 50% YoY.
- Glenmark's partner companies across Europe and EMs continue to witness a steady increase in market share across all its licensed markets.
- Glenmark and its partner in Mainland China, Grand Pharmaceutical (China) Co. Ltd., secured approval for RYALTRIS® in China in October 2025; the product is expected to be launched by Q1 FY27.
- Organon, Glenmark's partner in Thailand, is preparing to launch RYALTRIS® in Q4 FY26.

*Market share: Top 10 products within "R1A1 – Nasal Corticosteroids without Anti-Infectives" category as per IQVIA + RYALTRIS® as of September 2025

WINLEVI® PARTNERED WITH COSMO

- The Company launched WINLEVI® in the UK market in Q1 FY26 and saw a strong uptake throughout the year.
- Glenmark's partner Cosmo received MA approval for WINLEVI® in EU in October 2025. Glenmark is planning to initiate the commercial launch in its licensed EU territories by Q1 FY27.
- WINLEVI® is currently under regulatory review in South Africa, where Glenmark had submitted the MA application in 2024.

QiNHAYO™ (ENVAFOLIMAB) PARTNERED WITH JIANGSU ALPHAMAB & 3D MEDICINES

- Glenmark has filed QiNHAYO™ MA Applications in 18 markets till date; the first commercial launch is expected in FY27.
- The Company has received authorization from the regulatory authority in Kenya, Mauritius and Uganda for supply of QiNHAYO™ via early access programs or Named Patient Programs.
- Glenmark has also initiated a global multi-center Phase 3 study in resectable Stage III neo-adjuvant / adjuvant NSCLC in the neoadjuvant/adjuvant setting.

TRASTUZUMAB REZETECAN PARTNERED WITH HENGRUI PHARMA

- In Q3 FY26, Glenmark advanced its preparations for initiation of MA applications for Trastuzumab Rezetecan, a next-generation HER2-targeting antibody drug conjugate, in-licensed in Q2 FY26 from Jiangsu Hengrui Pharmaceuticals Co., Ltd. for several Emerging Markets. The Company expects the first wave of MA applications to begin Q1 FY27.
- Trastuzumab Rezetecan is Hengrui's self-developed HER2-targeted ADC. In Q1 FY26, it was approved and commercially launched in China for the treatment of adult patients with HER2 (ERBB2) activating mutations in unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
- In September 2025, the BLA for Trastuzumab Rezetecan in the 2L HER2+ breast cancer indication was accepted by China's NMPA for review and was included in the priority review program.
- This is the first China-developed ADC approved for HER2-mutated NSCLC. Currently, Trastuzumab Rezetecan is actively advancing multiple clinical trials. To date, Trastuzumab Rezetecan has been included in the NMPA's Breakthrough Therapy Designation list for nine indications covering multiple solid tumors.

AUMOLERTINIB PARTNERED WITH HANSOH PHARMA

- In Q3 FY26, Glenmark entered into an exclusive license, collaboration and distribution agreement with Hansoh Pharmaceutical Group Co. Ltd., for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC).
- Glenmark gained rights to develop, register and commercialize Aumolertinib across Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries.
- Thanks to its molecular design Aumolertinib Mesylate Tablets feature good liposolubility and stability, allowing it to better penetrate the blood-brain barrier with a low incidence of adverse reactions.

- Aumolertinib was approved in the UK in June 2025 for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. Hansoh also received a positive CHMP opinion in Q3 FY26, with MA grant in the EU expected in Q4 FY26.
- Aumolertinib is additionally approved in China for Maintenance therapy following CCRT in unresectable Stage III EGFR mutated NSCLC, as well as for Adjuvant treatment in sensitizing EGFR mutated resectable NSCLC. It is marketed for all 4 indications in China.
- Glenmark is preparing to initiate MA applications for Aumolertinib in H1 CY2026, with the first commercial launch anticipated during second half of FY27.

ICHNOS GLENMARK INNOVATION (IGI)

IGI features a robust pipeline of innovative Oncology molecules targeting Multiple Myeloma and solid tumors, of which ISB 2001 is in clinical development. Additionally, IGI has two autoimmune disease assets that have been out licensed to leading companies and are in clinical development:

Diversity Of Immune Cell Engagement And Indications Across Hematologic And Solid Tumours

ASSET	*DESCRIPTION*	INDICATION	DISCOVERY	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	GLOBAL RIGHTS
ISB 2001	*CD38 x BCMA x CD3 TREAT™ trispecific T-Cell Engager*	Multiple Myeloma						abbvie / Glenmark
ISB 880 / ALM27134	*IL-1RAP antagonist mAb*	Hidradenitis Suppurativa						almirall
Telazorlimab ISB 830-X8 / STAR-310	*OX40 antagonist mAb*	Atopic Dermatitis						astria
ISB 2301	*IMMUNITE™ NK-Cell Engager*	Solid Tumours						IGI
GRC 65327	*Cbl-b Inhibitor*	Solid Tumours						IGI

Oncology Immunology

ONCOLOGY

ISB 2001 TRISPECIFIC ANTIBODY

- ISB 2001/ABBV-2001 is a first-in-class trispecific T cell-engager that targets CD38 and BCMA on multiple myeloma cells and CD3 on T cells. It is a trispecific antibody based on IGI's proprietary BEAT® platform, allowing maximal flexibility and excellent manufacturability of full-length multispecific antibodies.
- In July 2025, IGI announced its partnership with AbbVie for ISB 2001. Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan and Greater China. IGI received an upfront payment of US$700 million in September 2025 post formal acceptance by the U.S. Federal Trade Commission (FTC) and is eligible to receive up to US$1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales. Glenmark Pharmaceuticals will develop, manufacture and lead commercialization of ISB 2001 across Emerging Markets including the rest of Asia, Latin America, Russia/CIS region, Middle East, Africa, Australia, New Zealand and South Korea.
- IGI is currently executing a Phase 1 study (TRIgnite-1) in Australia, United States and several European countries. The study continued to Dose Expansion in April 2025 and is continuing to rapidly enroll patients.

ISB 2301: IMMUNITE™ Platform

- ISB 2301 is a first-in-class multispecific NK cell-engager developed for solid tumors and the first program from IGI's IMMUNITE™ platform
- A Clinical Candidate was selected in October 2025, and the program has entered the IND-enabling stage

IMMUNOLOGY – PARTNERED PROGRAMS

IGI has two monoclonal antibody drug product candidates addressing autoimmune diseases in the pipeline. To enhance the company's focus on oncology, future development of both assets is overseen by out-licensing partners.

ISB 880/LAD191 (anti-IL-1RAP antagonist)

- ISB 880 was licensed to Almirall, S.A. in December 2021.
- The initiation of dosing in a Phase 1 study of ISB 880/ALM27134/LAD191 was announced by Almirall in September 2022. Almirall completed Phase I single and multiple ascending doses in

healthy volunteers, presenting the results at the recent European Academy of Dermatology and Venereology (EADV) 2025 congress as a late-breaking oral presentation

- Almirall's Phase 2 clinical study in Hidradenitis Suppurativa continues to advance, with ongoing patient recruitment and dosing reinforcing the program's strong operational progress. Almirall plans to initiate PoC study for additional inflammatory skin disease for the anti-IL-1RAP

ISB 830 (telazorlimab), ISB 830-X8/STAR-0310 (OX40 antagonist)

- ISB 830 and the OX40 antagonist platform were licensed to Astria Therapeutics in October 2023. Telazorlimab is an OX40 antagonist that successfully completed a Phase 2b study in moderate to severe Atopic Dermatitis (AD) in 2021.
- ISB 830-X8/STAR-0310 is in development for the treatment of Atopic Dermatitis and potentially other indications. STAR-0310 is a potential best-in-class, T-cell sparing, immunomodulating OX40 antagonist designed to have a long half-life.
- Phase 1 trial was initiated in the first quarter of 2025. Astria presented initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology & Venereology (EADV) Congress 2025 in a late-breaking oral presentation.
- Astria Therapeutics announced its acquisition by BioCryst. Building on the successful Phase 1b results, IGI in collaboration with Astria and BioCryst are actively evaluating the most promising path forward for ISB 830-X8 (STAR-0310), including engaging potential new partners to accelerate its development.

For further updates on IGI, including the pipeline assets, please log on to https://www.iginnovate.com/

#####